Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242706 (
hyperoxia
)
5,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously reported that rat pheochromocytoma PC12 cells express the neuronal differentiated phenotype under
hyperoxia
through the production of reactive oxygen species (ROS). In the present study, we found that in this phenotype, Bcl-2, an apoptosis inhibitor, affects mitogen-activated protein (MAP)-kinase activity, which is known as a key enzyme of the signal-transduction cascade for differentiation. When PC12 cells were cultured under
hyperoxia
, a rapid increase in MAP-kinase activity, including that of both p42 and
p44
, was observed. Although the activity level then decreased quickly, activity higher than the control level was observed for 48 h. PD98059, an inhibitor of MAP kinase, suppressed the
hyperoxia
-induced neurite extensions, suggesting the involvement of MAP-kinase activity in the mechanism of differentiation induced by ROS. An elevation of Bcl-2 expression was observed after culturing PC12 cells for 24 h under
hyperoxia
. This Bcl-2 elevation was not affected by treatment with PD98059, suggesting that it did not directly induce neurite extension under
hyperoxia
. However, the blockade of the Bcl-2 elevation by an antisense oligonucleotide inhibited the sustained MAP-kinase activity and neurite extensions under
hyperoxia
. Further, in PC12 cells highly expressing Bcl-2, the sustained MAP-kinase activity and neurite extensions under
hyperoxia
were enhanced. These results suggested that MAP kinase is activated through the production of ROS, and the subsequent elevation of Bcl-2 expression sustains the MAP-kinase activity, resulting in the induction of the neuronal-differentiation phenotype of PC12 cells under
hyperoxia
.
...
PMID:Hyperoxia induces the neuronal differentiated phenotype of PC12 cells via a sustained activity of mitogen-activated protein kinase induced by Bcl-2. 1002 24
We have previously demonstrated that the lungs of mice can exhibit increased programmed cell death or apoptosis after hyperoxic exposure in vivo. In this report, we show that hyperoxic exposure in vitro can also induce apoptosis in cultured murine macrophage cells (RAW 264.7) as assessed by DNA-laddering, terminal deoxynucleotidyltransferase dUTP nick end-labeling, and nucleosomal assays. To further delineate the signaling pathway of
hyperoxia
-induced apoptosis in RAW 264.7 macrophages, we first show that
hyperoxia
can activate the mitogen-activated protein kinase (MAPK) pathway, the extracellular signal-regulated kinases (ERKs) p42/
p44
, in a time-dependent manner as assessed by increased phosphorylation of ERK1/ERK2 by Western blot analyses. Neither the c-Jun NH(2)-terminal kinase/stress-activated protein kinase nor the p38 MAPK was activated by
hyperoxia
in these cells. Chemical or genetic inhibition of the ERK p42/
p44
MAPK pathway by PD-98059, a selective inhibitor of MAPK kinase, and dominant negative mutants of ERK, respectively, attenuated
hyperoxia
-induced apoptosis as assessed by DNA laddering and nucleosomal ELISAs. Taken together, our data suggest that
hyperoxia
can induce apoptosis in cultured murine macrophages and that the MAPK pathway mediates
hyperoxia
-induced apoptosis.
...
PMID:Mitogen-activated protein kinase pathway mediates hyperoxia-induced apoptosis in cultured macrophage cells. 1048 67
Here we discuss the morphological features and our current understanding of the pathways involved in non-apoptotic cell death from O2 toxicity. Preliminary data on hyperoxic signaling indicate that NF-kappa B translocation (and presumptive activation) is not a result of the p42/
p44
MAPK pathway, but a likely downstream consequence of activation of the JNK pathway. Our observations suggest the existence of multiple signal transduction pathways in
hyperoxia
-induced cell death: one involved in the stress response which appears to be NF-kappa B-dependent and another in cell death.
...
PMID:Hyperoxia in cell culture. A non-apoptotic programmed cell death. 1066 72
Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM). Intratumoral hypoxia is common in GBM and may be associated with the development of TMZ resistance. Oxygen therapy has previously been reported to potentiate the effect of chemotherapy in cancer. In this study, we investigated whether
hyperoxia
can enhance the TMZ-induced cytotoxicity of human GBM cells, and whether and how it would resensitize TMZ-resistant GBM cells to TMZ. TMZ-sensitive human GBM cells (D54-S and U87-S) were treated with TMZ to develop isogenic subclones of TMZ-resistant cells (D54-R and U87-R). All cell lines were then exposed to different oxygen levels (1, 21, 40, or 80 %), with or without concomitant TMZ treatment, before assessment of cell cytotoxicity and morphology. Cell death and survival pathways elicited by TMZ and/or
hyperoxia
were elucidated by western blotting. Our results showed that TMZ sensitivity of both chemo-sensitive and resistant cells was enhanced significantly under
hyperoxia
. At the cell line-specific optimum oxygen concentration (D54-R, 80 %; U87-R, 40 %), resistant cells had the same response to TMZ as the parent chemosensitive cells under normoxia via the caspase-dependent pathway. Both TMZ and
hyperoxia
were associated with increased phosphorylation of ERK
p44
/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of
hyperoxia
and TMZ-mediated cell death. Overall,
hyperoxia
enhanced TMZ toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. Induced
hyperoxia
is a potentially promising approach for treatment of TMZ-resistant GBM.
...
PMID:Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. 2276 62